Data suggests that people with MS treated with cladribine are able to mount a protective immune response after influenza and varicella zoster vaccination regardless of the timing of the vaccine relative to the cladribine dose and independent of lymphocyte counts. Real-world data has also shown that cladribine does not impair the humoral response to COVID-19 ...
Podcast: Prof Klaus Schmierer on vaccine readiness for people with MS on cladribine
21 Jun 2021
Sponsored by Merck Healthcare Pty Ltd